1. Home
  2. PT vs NLSP Comparison

PT vs NLSP Comparison

Compare PT & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PT
  • NLSP
  • Stock Information
  • Founded
  • PT 2012
  • NLSP 2015
  • Country
  • PT China
  • NLSP Switzerland
  • Employees
  • PT N/A
  • NLSP N/A
  • Industry
  • PT Computer Software: Programming Data Processing
  • NLSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • PT Technology
  • NLSP Health Care
  • Exchange
  • PT Nasdaq
  • NLSP Nasdaq
  • Market Cap
  • PT 14.7M
  • NLSP 12.4M
  • IPO Year
  • PT 2018
  • NLSP 2021
  • Fundamental
  • Price
  • PT $0.84
  • NLSP $1.65
  • Analyst Decision
  • PT
  • NLSP
  • Analyst Count
  • PT 0
  • NLSP 0
  • Target Price
  • PT N/A
  • NLSP N/A
  • AVG Volume (30 Days)
  • PT 140.9K
  • NLSP 896.1K
  • Earning Date
  • PT 09-19-2025
  • NLSP 10-06-2025
  • Dividend Yield
  • PT N/A
  • NLSP N/A
  • EPS Growth
  • PT N/A
  • NLSP N/A
  • EPS
  • PT N/A
  • NLSP N/A
  • Revenue
  • PT $4,961,892.00
  • NLSP N/A
  • Revenue This Year
  • PT N/A
  • NLSP N/A
  • Revenue Next Year
  • PT N/A
  • NLSP N/A
  • P/E Ratio
  • PT N/A
  • NLSP N/A
  • Revenue Growth
  • PT 9.20
  • NLSP N/A
  • 52 Week Low
  • PT $0.76
  • NLSP $1.30
  • 52 Week High
  • PT $1.38
  • NLSP $5.64
  • Technical
  • Relative Strength Index (RSI)
  • PT 38.92
  • NLSP 37.17
  • Support Level
  • PT $0.83
  • NLSP $1.45
  • Resistance Level
  • PT $0.90
  • NLSP $1.89
  • Average True Range (ATR)
  • PT 0.06
  • NLSP 0.17
  • MACD
  • PT -0.01
  • NLSP -0.03
  • Stochastic Oscillator
  • PT 11.94
  • NLSP 26.67

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Share on Social Networks: